Business Progress - The subsidiary Guangzhou Taihe Oncology Hospital has been approved to enter the "Hong Kong and Macau Drug and Device Access" list in the Guangdong-Hong Kong-Macao Greater Bay Area, allowing the introduction of innovative oncology drugs and devices that are already approved in Hong Kong and Macau but not yet in mainland China, potentially expanding business boundaries and strengthening competitive advantages [2] Executive Changes - On January 12, 2026, the company announced that Jiang Wei has taken over as president, which may influence the future strategic execution direction [3] Financial Performance - The latest financial report indicates that for the first half of 2025, the company achieved revenue of approximately 200 million, with losses narrowing by 2.9% year-on-year, although revenue decreased by 8.3% year-on-year. The operational commencement of the proton therapy center has improved the hospital business's gross margin, necessitating attention to the sustainability of future profitability [4]